RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2017 — BioCryst Pharmaceuticals, Inc. , a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that Health Canada has approved RAPIVAB i 1 2 , an intravenous treatment for acute, uncomplicated influenza.i 1 2 RAPIVAB is approved by the U.S. Food & Drug Administration and is also licensed for use in Japan and Taiwan as RAPIACTAi 1 2 and in Korea as PeramiFlui 1 2.i 1 2 i 1 2This RAPIVAB approval represents an important milestone for BioCryst and for our partner, Seqirus,i 1 2 said Jon P. Stonehouse, President & Chief Executive Officer .i 1 2 i 1 2We are excited that patients in Canada will soon have an I.V. option for the treatment of influenza infections.i 1 2i 1 2 RAPIVAB is being commercialized by Seqirus globally, excluding Japan, Taiwan, Korea and Israel.i 1 2 Seqirus is a … (more)